Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease.

Ryska O., Serclova Z., Mestak O., Matouskova E., Vesely P., Mrazova I.

Randomized Controlled Trial with a reported sample of 16 on Chronic Wound, Autoimmune Research, published in Scand J Gastroenterol (2017) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Scand J Gastroenterol (2017)
Country
England
Reported sample size
16
Source database
PubMed
PMID
28116942
DOI
10.1080/00365521.2017.1281434
Citations
13

Abstract (original English)

Objective Local application of adipose-derived mesenchymal stem cells (ADSC) represents a novel approach for the management of perianal fistula in patients with Crohn's disease. A randomised study on an animal model was performed to investigate the efficacy and to detect the distribution of implanted ADSCs by bioluminescence (BLI). Materials and methods A caecostomy was used as a fistula model in 32 Lewis rats. The ADSCs were isolated from transgenic donor expressing firefly luciferase. Animals were randomly assigned to groups given injections of 4 × 10 6 cells (n = 16, group A) or placebo (n = 16, group B) in the perifistular tissue. Fistula drainage assessment was used to evaluate the fistula healing. After application of D-luciferin, cell viability and distribution was detected using an IVIS Lumina XR camera on days 0, 2, 7, 14 and 30. Results The fistula was identified as healed in 6 (38%) animals in group A vs. 1 case (6.3%) in group B (p = .033). The BLI was strongest immediately after administration of ADSCs 31.2 × 10 4 (6.09-111 × 10 4 ) p/s/cm 2 /sr. The fastest decrease was observed within the first 2 days when values fell by 50.2%. The BLI 30 days after injection was significantly higher in animals with healed fistulas - 8.23 × 10 4 (1.18-16.9 × 10 4 ) vs. 1.74 × 10 4 (0.156-6.88 × 10 4 ); p = .0393. Conclusions Local application of ADSCs resulted in significantly hi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAnimalsCrohn DiseaseDisease Models, AnimalLuminescent MeasurementsMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsProspective StudiesRandom Allocation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research